ENVALITH
株式会社ADR120S logo

Cytori Cell Research Institute,Inc.

3750・Standard Market・Information & Communication

Official website
株式会社ADR120S logo
Cytori Cell Research Institute,Inc.3750

Business

ADR120S Inc. is a regenerative medicine-focused group (8 consolidated subsidiaries) listed on the Standard Market of the Tokyo Stock Exchange. Its core subsidiary, ADR Therapeutics Co., Ltd., sells the "Celution Centrifuge," a medical device, and the "Cell Therapy Kit," a Class III controlled medical device, to domestic medical institutions. The company holds patented technology that harvests and transplants adipose-derived regenerative cells (ADRCs) from a patient's own subcutaneous fat within a few hours, achieving differentiation through no need for cell culturing and avoidance of rejection reactions. For the treatment of male stress urinary incontinence, the company obtained manufacturing and marketing approval from the Ministry of Health, Labour and Welfare in February 2022, and is currently pursuing an application for insurance coverage. The former Real Asset Business completed its liquidation with the final real estate transfer in May 2025, and the company is now concentrating its management resources on the Medical Business.

Business Model

ADR Therapeutics Co., Ltd. generates equipment and consumable revenue by selling Celution Centrifuge and Cell Therapy Kit products to medical institutions. In parallel, Cytori Cell Therapy Co., Ltd., Kyoseikai, and Animal Therapy Co., Ltd. provide cell therapy services in the free-choice (out-of-insurance) medical field, building up service revenue. The core products are transitioning from overseas imports to domestically produced items, with the aim of improving the revenue structure through cost reduction and stable procurement.

Company Strengths

The Celution Centrifuge received medical device approval in 2012, and the Cell Therapy Kit obtained Class III Controlled Medical Device approval in 2018. Manufacturing and marketing approval for the treatment of male stress urinary incontinence (SUI) was obtained in February 2022, giving the company an early approval track record in the regenerative medicine field, which has high regulatory entry barriers.

The company holds patented technology that harvests ADRCs from a patient's own subcutaneous fat in a few hours, allowing treatment to be completed the same day without cell culturing. This differentiates the technology from competing approaches by avoiding rejection risk while isolating the full range of stem cells naturally present in adipose tissue without artificial manipulation.

Sales of the domestically produced Cell Therapy Kit began in February 2026. The Celution Centrifuge has also completed product development and is scheduled for full-scale sales launch in August 2026, completing the establishment of a domestic manufacturing system that moves away from dependence on overseas imports. This is expected to achieve stable procurement, quality improvement, and cost reduction.

ENVALITH's Perspective

Net assets at the end of FY2026 (ending March 2026) stood at ¥22 million (equity ratio of 6.0%), with cash and cash equivalents limited to ¥125 million. Operating cash flow continued to show a persistent outflow of ¥784 million, and the financial statements include a note on material uncertainty regarding the going concern assumption. Although the financial structure has improved through support from HG Capital and the sale of real estate, if the FY2027 (ending March 2027) earnings forecast (net sales of ¥750 million, net income of ¥20 million) fails to be achieved, the risk that cash flow pressures will intensify again cannot be ruled out.

The recovery from net sales of ¥51 million in FY2026 (ending March 2026) to a forecast of ¥750 million in FY2027 (ending March 2027) (a year-on-year increase of 1,470.9%) is premised on the full-scale launch of sales of the Celution Centrifuge (Domestic Product) starting in August 2026 and the transition of the Neocella business into a revenue-generating phase. However, if responses to semiconductor supply constraints or final adjustments to mass production systems are delayed again, there is a risk that the timing of sales recognition could be pushed back once more. There is a track record of changes to sales timing in the past, and the probability of achieving the forecast needs to be carefully assessed.

If insurance coverage for male stress urinary incontinence (SUI) treatment is realized, patient access is expected to improve significantly due to reduced treatment cost burdens, structurally expanding demand for the Celution Centrifuge and Cell Therapy Kit. However, the review and decision on insurance coverage are external factors dependent on the judgment of administrative authorities, and the timing and conditions cannot be controlled solely by the company's efforts. At present, the specific timing of insurance coverage remains undetermined, and this should be recognized as a factor that increases uncertainty in the monetization scenario.

Growth Strategy

Aiming for a return to profitability in FY2027 (ending March 2027) through the full-scale sales launch of domestically produced medical devices and the new Neocella business

Product development has already been completed, and the business is in the final adjustment stage toward a mass-production system. Sales launch timing has been set for August 2026, prioritizing responses to global semiconductor supply constraints and quality assurance. Full-scale sales are expected to be the primary driver of a significant recovery in net sales in FY2027 (ending March 2027) (forecast: ¥750 million).

Sales of the domestic product have already begun as of February 2026. The shift from overseas imports to the domestic product has achieved stable procurement, quality improvement, and cost reduction. Sales expansion to both existing and new business partners will be actively pursued.

Manufacturing and marketing approval was obtained from the Ministry of Health, Labour and Welfare in February 2022. If insurance coverage is realized, the treatment cost burden on patients will be reduced, structurally expanding demand for the Celution Centrifuge and Cell Therapy Kit. Procedures toward insurance coverage are currently ongoing.

Regarding the high-concentration exosome component-containing solution business (Neocella, formerly known as CrymEX) announced as of September 30, 2025, development expenses were recorded in FY2026 (ending March 2026) to establish the business foundation. Going forward, without additional development investment, the business is expected to transition to a revenue-generating phase through product supply and collaboration with partner institutions. Expansion into medical needs such as sports medicine, joint conditions, and musculoskeletal disorders is also being pursued.

The long-term borrowings were fully repaid using ¥2,944 million in proceeds from the transfer of real estate (trust beneficiary interests). Debt forgiveness of ¥400 million from HG Capital (as of March 27, 2026) and the maintenance of a commitment line with an upper limit of ¥500 million were secured, establishing the funding base necessary for business development in FY2027 (ending March 2027).

Last updated: July 19, 2026